161 related articles for article (PubMed ID: 34793441)
1. A Phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model.
Erdem R; Ambler G; Al-Ibrahim M; Fraczek K; Dong SD; Gast C; Mercer LD; Raine M; Tennant SM; Chen WH; de Hostos EL; Choy RKM
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009969. PubMed ID: 34793441
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
[TBL] [Abstract][Full Text] [Related]
3. Developing novel antisecretory drugs to treat infectious diarrhea.
de Hostos EL; Choy RK; Nguyen T
Future Med Chem; 2011 Aug; 3(10):1317-25. PubMed ID: 21859305
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.
Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP
Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960
[TBL] [Abstract][Full Text] [Related]
5. A Potent Inhibitor of the Cystic Fibrosis Transmembrane Conductance Regulator Blocks Disease and Morbidity Due to Toxigenic
Rivera-Chávez F; Meader BT; Akosman S; Koprivica V; Mekalanos JJ
Toxins (Basel); 2022 Mar; 14(3):. PubMed ID: 35324722
[No Abstract] [Full Text] [Related]
6. New drug targets for cholera therapy.
Thiagarajah JR; Verkman AS
Trends Pharmacol Sci; 2005 Apr; 26(4):172-5. PubMed ID: 15808339
[TBL] [Abstract][Full Text] [Related]
7. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
[TBL] [Abstract][Full Text] [Related]
8. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139.
Khan WA; Bennish ML; Seas C; Khan EH; Ronan A; Dhar U; Busch W; Salam MA
Lancet; 1996 Aug; 348(9023):296-300. PubMed ID: 8709688
[TBL] [Abstract][Full Text] [Related]
9. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
[TBL] [Abstract][Full Text] [Related]
10. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
[TBL] [Abstract][Full Text] [Related]
11. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.
Trach DD; Clemens JD; Ke NT; Thuy HT; Son ND; Canh DG; Hang PV; Rao MR
Lancet; 1997 Jan; 349(9047):231-5. PubMed ID: 9014909
[TBL] [Abstract][Full Text] [Related]
12. Tetracycline in the treatment of severe cholera due to Vibrio cholerae O139 Bengal.
Hossain MS; Salam MA; Rabbani GH; Kabir I; Biswas R; Mahalanabis D
J Health Popul Nutr; 2002 Mar; 20(1):18-25. PubMed ID: 12022154
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiological mechanisms of diarrhea caused by the Vibrio cholerae O1 El Tor variant: an in vivo study in mice.
Satitsri S; Pongkorpsakol P; Srimanote P; Chatsudthipong V; Muanprasat C
Virulence; 2016 Oct; 7(7):789-805. PubMed ID: 27222028
[TBL] [Abstract][Full Text] [Related]
14. Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins.
Rabbani GH
Dan Med Bull; 1996 Apr; 43(2):173-85. PubMed ID: 8741209
[TBL] [Abstract][Full Text] [Related]
15. Emergence of Vibrio cholerae O1 biotype El Tor serotype Inaba causing outbreaks of cholera in Orissa, India.
Pal BB; Khuntia HK; Samal SK; Das SS; Chhotray GP
Jpn J Infect Dis; 2006 Aug; 59(4):266-9. PubMed ID: 16936349
[TBL] [Abstract][Full Text] [Related]
16. Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial.
Rabbani GH; Islam MR; Butler T; Shahrier M; Alam K
Antimicrob Agents Chemother; 1989 Sep; 33(9):1447-50. PubMed ID: 2684006
[TBL] [Abstract][Full Text] [Related]
17. A randomized double blind trial of aspirin versus placebo in cholera and non-cholera diarrhoea.
Islam A; Bardhan PK; Islam MR; Rahman M
Trop Geogr Med; 1986 Sep; 38(3):221-5. PubMed ID: 3529538
[TBL] [Abstract][Full Text] [Related]
18. AC6 is the major adenylate cyclase forming a diarrheagenic protein complex with cystic fibrosis transmembrane conductance regulator in cholera.
Thomas A; Ramananda Y; Mun K; Naren AP; Arora K
J Biol Chem; 2018 Aug; 293(33):12949-12959. PubMed ID: 29903911
[TBL] [Abstract][Full Text] [Related]
19. Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation.
Pongkorpsakol P; Satitsri S; Wongkrasant P; Chittavanich P; Kittayaruksakul S; Srimanote P; Chatsudthipong V; Muanprasat C
Eur J Pharmacol; 2017 Mar; 798():94-104. PubMed ID: 28119077
[TBL] [Abstract][Full Text] [Related]
20. Discovery and development of antisecretory drugs for treating diarrheal diseases.
Thiagarajah JR; Ko EA; Tradtrantip L; Donowitz M; Verkman AS
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):204-9. PubMed ID: 24316107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
